In particular, the patents cover the selection of NSCLC patients for treatment with antibodies directed against the epidermal growth-factor receptor (EGFR) pathway.
The patents also cover the selection of colorectal cancer patients for treatment with drugs targeting the EGFR pathway and the selection of head and neck cancer patients for treatment with drugs targeting the EGFR pathway.
Further the patents cover the company’s laboratory operations: a method and system for determining whether a drug will be effective on a patient with a disease (7,879,620), a continuation of the company’s foundational ‘905 patent awarded in June 2010.
The patents provide additional coverage in multiple tumor types for the Biodesix’s first product, VeriStrat.
VeriStrat, a serum proteomic test, helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).
VeriStrat is based on ProTS, a proprietary technology which enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy.
The ProTS platform provides the foundation for collaborations with researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies.
"The issuance of these patents recognizes our approach and innovation in delivering rapid turnaround, serum-based tests to the oncology community as unique," commented David Brunel, Biodesix CEO. "Our latest patents enhance the overall commercial profile of VeriStrat and strengthen our IP portfolio in molecular diagnostics."
